The National Pharmaceutical Council (NPC) today announced that Mark J. Nagy, Vice President, Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, has been elected chairman of NPC's Board of Directors for 2017-2018. Mr. Nagy has previously served in several leadership roles at NPC, most recently as Vice Chair.

"Mark's experience and thoughtful guidance on some of our most pressing health care challenges will be greatly appreciated during his tenure as Chairman," said NPC President Dan Leonard. "We're looking forward to working with him, especially at a time when real-world evidence, health care spending and other emerging issues are coming to the forefront of health care policy debates."

NPC's Board of Directors also elected other members to its executive committee:

• Richard H. Bagger (Vice Chair), Executive Vice President, Corporate Affairs and Market Access, Celgene Corporation;
• Don Sawyer (Treasurer), Senior Vice President, Market Access, Bayer HealthCare Pharmaceuticals;
• Joshua J. Ofman (Immediate Past Chair), Senior Vice President, Global Value, Access & Policy Amgen Inc.;
• Patrick Magri (At-large), Senior Vice President, Managed Markets and Policy, Merck.

Mr. Nagy has had a long and distinguished career at Lilly since joining in 1989. He has worked in a number of positions of increasing responsibility across the company, both in the U.S. and abroad. Prior to becoming Vice President of Global Patient Outcomes and Real World Evidence, Mr. Nagy was the Senior Marketing Director, Managed Health Care Services, Payer Marketing, in which he oversaw strategies and plans for the company related to U.S. healthcare reform. Previous roles at Lilly have included global marketing director, U.S. brand leader, senior director of global marketing and sales capabilities, and U.S. neuroscience marketing director.

"It is an honor to be elected as the chairman of NPC's Board of Directors at a time of such change in the U.S. health care system," Mr. Nagy said. "NPC is at the leading edge of the conversation on critical health policy issues, like real-world evidence, value and patient outcomes. I look forward to working with all of my fellow Board members as we work to further the mission of NPC and promote its work to foster a supportive environment for medical innovation."

As the health policy debate has focused more on evidence and quality as drivers for change in the health care system, NPC has filled an important role in the discussion by supporting and conducting peer-reviewed research focused on evidence, the value of medicines for patients, and innovation. For more than 60 years, the organization has focused on advancing research, information dissemination, and education.

About the National Pharmaceutical Council

The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation's major research-based pharmaceutical companies, NPC focuses on research development, information dissemination and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit www.npcnow.org and follow NPC on Twitter @npcnow.